Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
go back to main search page
Accession:CHEBI:62913 term browser browse the term
Definition:An EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of a NAD(+) ADP-ribosyltransferase (EC 2.4.2.30).
Synonyms:related_synonym: ADP-ribosyltransferase (polymerising) inhibitor;   ADP-ribosyltransferase (polymerising) inhibitors;   ADP-ribosyltransferase (polymerizing) inhibitor;   ADP-ribosyltransferase (polymerizing) inhibitors;   EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitors;   EC 2.4.2.30 inhibitor;   EC 2.4.2.30 inhibitors;   NAD(+) ADP-ribosyltransferase inhibitor;   NAD(+) ADP-ribosyltransferase inhibitors;   NAD(+):poly(ADP-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitor;   NAD(+):poly(ADP-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitors;   NAD(+):poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitor;   NAD(+):poly(adenosine-diphosphate-D-ribosyl)-acceptor ADP-D-ribosyl-transferase inhibitors;   PARP;   PARPs;   poly(ADP-ribose) polymerase inhibitor;   poly(ADP-ribose) polymerase inhibitors;   poly(ADP-ribose) synthase inhibitor;   poly(ADP-ribose) synthase inhibitors;   poly(ADP-ribose) synthetase inhibitor;   poly(ADP-ribose) synthetase inhibitors;   poly(adenosine diphosphate ribose) polymerase inhibitor;   poly(adenosine diphosphate ribose) polymerase inhibitors
 xref: Wikipedia:PARP_inhibitor



show annotations for term's descendants           Sort by:
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
JBrowse link
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Retn resistin multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
3-aminobenzamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]
3-aminobenzamide promotes the reaction [Alitretinoin promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]]; 3-aminobenzamide promotes the reaction [Alitretinoin results in increased expression of ABCA1 mRNA]; 3-aminobenzamide promotes the reaction [T0901317 results in increased expression of ABCA1 mRNA]
CTD PMID:27026705 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases expression EXP
ISO
3-aminobenzamide results in increased expression of ADIPOQ mRNA CTD PMID:18815186 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Adipor1 adiponectin receptor 1 increases expression ISO
EXP
3-aminobenzamide results in increased expression of ADIPOR1 mRNA CTD PMID:18815186 NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
JBrowse link
G Adipor2 adiponectin receptor 2 increases expression EXP
ISO
3-aminobenzamide results in increased expression of ADIPOR2 mRNA CTD PMID:18815186 NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of ATM protein] CTD PMID:22226932 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO 3-aminobenzamide results in increased expression of BGLAP mRNA CTD PMID:15670817 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Casp3 caspase 3 multiple interactions EXP
ISO
3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]
3-aminobenzamide inhibits the reaction [[oxyhyponitrite results in increased abundance of nitroxyl] which results in increased activity of CASP3 protein]
CTD PMID:11744336 PMID:16505238 PMID:30377735 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] CTD PMID:16505238 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO 3-aminobenzamide results in decreased expression of CCND1 mRNA CTD PMID:15670817 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cd36 CD36 molecule increases expression EXP 3-aminobenzamide results in increased expression of CD36 mRNA CTD PMID:18815186 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO 3-aminobenzamide results in increased expression of CDKN1A mRNA CTD PMID:15670817 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Ctnnb1 catenin beta 1 decreases expression ISO 3-aminobenzamide results in decreased expression of CTNNB1 mRNA CTD PMID:15670817 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Bleomycin results in increased secretion of CXCL2 protein] CTD PMID:26600069 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein] CTD PMID:15670817 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
JBrowse link
G Ep300 E1A binding protein p300 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of EP300 mRNA] CTD PMID:22228707 NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression
ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC1 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA]
3-aminobenzamide results in decreased expression of ERCC1 mRNA; 3-aminobenzamide results in decreased expression of ERCC1 protein
CTD PMID:22228707 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit multiple interactions
decreases expression
ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA]
3-aminobenzamide results in decreased expression of ERCC4 mRNA; 3-aminobenzamide results in decreased expression of ERCC4 protein
CTD PMID:22228707 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
affects response to substance
ISO 3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to 3-aminobenzamide
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Fn1 fibronectin 1 multiple interactions
decreases expression
ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of FN1 mRNA]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]
3-aminobenzamide results in decreased expression of FN1 protein
CTD PMID:22228707 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of HRAS protein] CTD PMID:26047893 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Id2 inhibitor of DNA binding 2 decreases expression ISO 3-aminobenzamide results in decreased expression of ID2 mRNA CTD PMID:15670817 NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] CTD PMID:19962977 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Ins2 insulin 2 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression ISO 3-aminobenzamide results in decreased expression of JUN mRNA CTD PMID:15670817 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Lep leptin increases expression EXP 3-aminobenzamide results in increased expression of LEP mRNA CTD PMID:18815186 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lpl lipoprotein lipase increases expression EXP 3-aminobenzamide results in increased expression of LPL mRNA CTD PMID:18815186 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO
EXP
3-aminobenzamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]
3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA mRNA]; 3-aminobenzamide inhibits the reaction [Glucose results in decreased expression of MAFA protein]
CTD PMID:16505238 NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690
JBrowse link
G Mir126a microRNA 126a decreases expression
multiple interactions
ISO 3-aminobenzamide results in decreased expression of MIR126 mRNA
3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]; [Decitabine co-treated with 3-aminobenzamide] inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA]
CTD PMID:32006662 NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MPO protein] CTD PMID:19962977 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO 3-aminobenzamide results in decreased expression of MYC mRNA CTD PMID:15670817 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO 3-aminobenzamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFKBIA mRNA] CTD PMID:19962977 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases ADP-ribosylation ISO 3-aminobenzamide results in decreased ADP-ribosylation of NR1H3 protein CTD PMID:27026705 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
ISO
EXP
3-aminobenzamide inhibits the reaction [Asbestos, Amosite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Asbestos, Crocidolite results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Benzoyl Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased ADP-ribosylation of PARP1 protein modified form]; 3-aminobenzamide inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [hydroquinone results in increased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Lithocholic Acid analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [mezerein results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to [Potassium Dichromate co-treated with nickel sulfate]]; 3-aminobenzamide inhibits the reaction [Smoke analog results in increased activity of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]; 3-aminobenzamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein]; 3-aminobenzamide promotes the reaction [Capsaicin results in increased expression of PARP1 protein]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [3-aminobenzamide results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin
3-aminobenzamide inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased cleavage of PARP1 protein]; 3-aminobenzamide inhibits the reaction [sodium arsenite results in increased cleavage of PARP1 protein]
3-aminobenzamide inhibits the reaction [PARP1 protein results in increased susceptibility to Acetaminophen]
CTD PMID:2120135 PMID:2126186 PMID:11217149 PMID:15075382 PMID:15601672 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 affects binding ISO PARP2 protein binds to 3-aminobenzamide CTD PMID:20092359 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression EXP 3-aminobenzamide results in increased expression of PCNA protein CTD PMID:11049868 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 multiple interactions EXP 3-aminobenzamide inhibits the reaction [Palmitic Acid results in decreased expression of PDX1 protein] CTD PMID:19513971 NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases activity
multiple interactions
decreases ADP-ribosylation
EXP 3-aminobenzamide results in increased activity of PPARG protein
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein]
3-aminobenzamide results in decreased ADP-ribosylation of PPARG protein
CTD PMID:18815186 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Prkdc protein kinase, DNA-activated, catalytic subunit multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of PRKDC protein] CTD PMID:22226932 NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO 3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]; 3-aminobenzamide results in decreased phosphorylation of and results in increased activity of RB1 protein CTD PMID:15670817 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP 3-aminobenzamide inhibits the reaction [Methylnitrosourea results in decreased expression of RELA protein modified form] CTD PMID:17137578 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Sfrp1 secreted frizzled-related protein 1 multiple interactions EXP 3-aminobenzamide inhibits the reaction [SFRP1 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]] CTD PMID:30377735 NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO 3-aminobenzamide results in increased expression of SPP1 mRNA CTD PMID:15670817 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO 3-aminobenzamide inhibits the reaction [resveratrol results in increased phosphorylation of STK11 protein] CTD PMID:19620254 NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO 3-aminobenzamide inhibits the reaction [TERT protein mutant form results in decreased susceptibility to temozolomide] CTD PMID:12488552 NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO 3-aminobenzamide inhibits the reaction [Capsaicin results in increased expression of TP53 protein]; 3-aminobenzamide inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] CTD PMID:22226932 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
isoquinoline-1,5-diol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [1,5-dihydroxyisoquinoline co-treated with Tretinoin] results in decreased expression of BCL2 protein CTD PMID:10713328 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Edn1 endothelin 1 decreases expression EXP 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 mRNA; 1,5-dihydroxyisoquinoline results in decreased expression of EDN1 protein CTD PMID:12824290 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Ednra endothelin receptor type A decreases expression EXP 1,5-dihydroxyisoquinoline results in decreased expression of EDNRA mRNA CTD PMID:12824290 NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
JBrowse link
G Ednrb endothelin receptor type B decreases expression EXP 1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA CTD PMID:12824290 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein] CTD PMID:25517228 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
decreases expression
EXP
ISO
1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein]
1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]
1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein
CTD PMID:12824290 PMID:19833176 PMID:25517228 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]] CTD PMID:25517228 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199 PMID:29281794 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 increases activity ISO Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
JBrowse link
G Agt angiotensinogen multiple interactions ISO Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Alb albumin multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in decreased expression of ALB protein] CTD PMID:33404076 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP
ISO
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein]
CTD PMID:31376360 PMID:33404076 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] CTD PMID:33404076 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124 PMID:14499179 NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression EXP Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in increased expression of IL6 protein] CTD PMID:33404076 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in increased expression of NOS2 protein] CTD PMID:33404076 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein] CTD PMID:33404076 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP
ISO
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein]
CTD PMID:31376360 PMID:33404076 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
ISO
EXP
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions IEP nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Abca1 protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases phosphorylation
ISO
EXP
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975 PMID:19071085 PMID:21212096 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA] CTD PMID:37120126 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ace2 angiotensin converting enzyme 2 multiple interactions ISO 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA] CTD PMID:37120126 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Acta2 actin alpha 2, smooth muscle increases expression EXP Niacinamide results in increased expression of ACTA2 mRNA; Niacinamide results in increased expression of ACTA2 protein CTD PMID:38555046 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
ISO
EXP
Niacinamide results in increased secretion of ADIPOQ protein
[Alloxan co-treated with Niacinamide] affects the expression of ADIPOQ protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443 PMID:21439372 PMID:26429928 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP
ISO
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]
CTD PMID:18420994 PMID:37120126 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein] CTD PMID:37566541 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
EXP
ISO
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987 PMID:16998810 PMID:25478867 PMID:26712469 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572 PMID:25478867 PMID:26712469 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572 PMID:26712469 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238 PMID:24040102 PMID:24962570 PMID:25478867 PMID:26712469 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238 PMID:25478867 PMID:26712469 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
CTD PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More... NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
JBrowse link
G Cd36 CD36 molecule decreases expression EXP nicotinamide decreases expression of Cd36 protein in kidney RGD PMID:19878707 RGD:2326081 NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109 PMID:22561310 PMID:25478867 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
multiple interactions
EXP Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520 PMID:25707573 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression EXP Nicotinamide decreases expression of Cpt1a protein in kidney of 5/6 nephrectomized rats RGD PMID:19878707 RGD:2326081 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA] CTD PMID:37120126 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Defb5 defensin beta 5 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467
JBrowse link
G Dicer1 dicer 1 ribonuclease III multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762 PMID:20169165 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G F3 coagulation factor III, tissue factor decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G Fabp1 fatty acid binding protein 1 multiple interactions EXP nicotinamide inhibits the reaction [5/6 nephrectomy decreases the expression of Fabp1 protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544 PMID:20181797 PMID:26712469 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493 PMID:25472572 PMID:26712469 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
JBrowse link
G Fth1 ferritin heavy chain 1 increases expression ISO Niacinamide results in increased expression of FTH1 mRNA; Niacinamide results in increased expression of FTH1 protein CTD PMID:23738040 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA] CTD PMID:16917544 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gcg glucagon multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
EXP Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
JBrowse link
G Glo1 glyoxalase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein] CTD PMID:32894639 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516 PMID:21439372 PMID:32894639 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein] CTD PMID:32894639 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions
decreases expression
EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]
Nicotinamide decreases expression of Hmgcr protein in kidney of 5/6 nephrectomized rats
CTD
RGD
PMID:20696151 PMID:21212096 PMID:19878707 RGD:2326081 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Il10 interleukin 10 multiple interactions ISO 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein] CTD PMID:37120126 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il18 interleukin 18 multiple interactions EXP [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA CTD PMID:28322830 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023 PMID:20307516 PMID:21439372 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins1 insulin 1 multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein]; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein] CTD PMID:16366736 PMID:19647726 PMID:21382363 PMID:21630391 PMID:25999625 More... NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Insr insulin receptor multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein] CTD PMID:37566541 NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
JBrowse link
G Irs2 insulin receptor substrate 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein] CTD PMID:37566541 NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP
ISO
[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; Niacinamide inhibits the reaction [Acetaminophen results in increased expression of KEAP1 protein]
CTD PMID:21439372 PMID:33949241 PMID:37120126 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Klf4 KLF transcription factor 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA] CTD PMID:31081965 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mir200a microRNA 200a multiple interactions ISO 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]; [Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A] CTD PMID:37120126 NCBI chr 5:166,648,494...166,648,582 JBrowse link
G Mir3545 microRNA 3545 multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656
JBrowse link
G Mlxipl MLX interacting protein-like multiple interactions EXP nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Mlxipl protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I increases expression ISO Niacinamide results in increased expression of COX1 mRNA; Niacinamide results in increased expression of COX1 protein CTD PMID:23738040 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816 PMID:24792773 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NAMPT protein]
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469 PMID:32298659 PMID:33949241 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP
ISO
[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; [Niacinamide co-treated with Acetaminophen] affects the localization of NFE2L2 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]
CTD PMID:21439372 PMID:33949241 PMID:37120126 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA] CTD PMID:32894639 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA] CTD PMID:37120126 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
decreases activity
EXP
ISO
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Niacinamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987 PMID:19288225 PMID:26712469 PMID:29143419 PMID:36958258 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
JBrowse link
G Pdp1 pyruvate dehydrogenase phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO
EXP
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]
CTD PMID:22539994 PMID:37566541 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085 PMID:23422569 PMID:23891692 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pygl glycogen phosphorylase L multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; [Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; Niacinamide inhibits the reaction [Resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More... NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression
multiple interactions
increases expression
ISO
EXP
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520 PMID:22539994 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Scaf1 SR-related CTD-associated factor 1 increases expression EXP nicotinamide increases expression of Scaf1 protein in kidney RGD PMID:19878707 RGD:2326081 NCBI chr 1:95,485,448...95,499,389
Ensembl chr 1:95,485,448...95,496,029
JBrowse link
G Scap SREBF chaperone increases expression IEP nicotinamide increases expression of Scap protein in kidney of 5/6 nephrectomized rat RGD PMID:19878707 RGD:2326081 NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
JBrowse link
G Scarb1 scavenger receptor class B, member 1 decreases expression EXP nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Scarb1 protein in kidney] RGD PMID:19878707 RGD:2326081 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425 PMID:24557422 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More... NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628 PMID:26712469 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]; Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein] CTD PMID:32298659 PMID:37566541 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
G Smad3 SMAD family member 3 increases phosphorylation
increases expression
EXP Niacinamide results in increased phosphorylation of SMAD3 protein
Niacinamide results in increased expression of SMAD3 mRNA
CTD PMID:38555046 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
JBrowse link
G Smad7 SMAD family member 7 decreases expression EXP Niacinamide results in decreased expression of SMAD7 mRNA; Niacinamide results in decreased expression of SMAD7 protein CTD PMID:38555046 NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
JBrowse link
G Snap23 synaptosome associated protein 23 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP
ISO
[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]
CTD PMID:31081965 PMID:37120126 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692 PMID:25472572 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Stx4 syntaxin 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
ISO
EXP
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]
Niacinamide results in increased expression of TGFB1 mRNA; Niacinamide results in increased expression of TGFB1 protein
CTD PMID:37120126 PMID:38555046 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B decreases expression ISO Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
G Tnfsf11 TNF superfamily member 11 decreases expression ISO Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tyr tyrosinase increases expression ISO Niacinamide results in increased expression of TYR mRNA; Niacinamide results in increased expression of TYR protein CTD PMID:23738040 NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
JBrowse link
niraparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G H2ax H2A.X variant histone increases expression
multiple interactions
ISO niraparib results in increased expression of H2AX protein
diphenyleneiodonium inhibits the reaction [niraparib results in increased expression of H2AX protein]
CTD PMID:34396909 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO niraparib binds to and results in decreased activity of PARP1 protein CTD PMID:28001384 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 multiple interactions ISO niraparib binds to and results in decreased activity of PARP2 protein CTD PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
NU 1025 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions
affects response to substance
ISO NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]
ERCC6 gene mutant form affects the susceptibility to NU 1025
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
olaparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of ACACA mRNA CTD PMID:27984176 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Acacb acetyl-CoA carboxylase beta multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of ACACB mRNA CTD PMID:27984176 NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
JBrowse link
G Acox1 acyl-CoA oxidase 1 multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of ACOX1 mRNA CTD PMID:27984176 NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] CTD PMID:27984176 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adgre1 adhesion G protein-coupled receptor E1 multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 mRNA] CTD PMID:27984176 NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of AIFM1 protein] CTD PMID:35396826 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO olaparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; olaparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] CTD PMID:30296409 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bap1 BRCA1 associated deubiquitinase 1 increases response to substance ISO BAP1 gene mutant form results in increased susceptibility to olaparib CTD PMID:22683710 NCBI chr16:6,446,709...6,455,535
Ensembl chr16:6,446,709...6,455,535
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO INCB054329 promotes the reaction [olaparib results in increased expression of BAX protein] CTD PMID:29567272 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO olaparib results in decreased expression of BCL2 protein CTD PMID:25531448 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO olaparib results in decreased expression of BIRC5 protein CTD PMID:25531448 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Brca1 BRCA1, DNA repair associated affects response to substance
multiple interactions
ISO BRCA1 affects the susceptibility to olaparib
[BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [olaparib co-treated with INCB054329] results in decreased expression of BRCA1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of BRCA1 protein]
CTD PMID:21633166 PMID:29567272 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brca2 BRCA2, DNA repair associated affects response to substance ISO BRCA2 affects the susceptibility to olaparib CTD PMID:21633166 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Brd4 bromodomain containing 4 multiple interactions
affects response to substance
ISO [BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of BRCA1 protein; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein CTD PMID:29567272 NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP3 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of CASP3 protein] CTD PMID:25531448 PMID:26544897 PMID:35396826 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased cleavage of CASP8 protein]; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein] CTD PMID:25531448 PMID:26544897 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CASP9 protein] CTD PMID:25531448 PMID:35396826 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO olaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein] CTD PMID:29317476 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCN2 mRNA] CTD PMID:27984176 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [olaparib co-treated with INCB054329] results in decreased expression of CCNE1 protein; olaparib promotes the reaction [INCB054329 results in decreased expression of CCNE1 protein] CTD PMID:29567272 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CCR2 mRNA CTD PMID:27984176 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
ISO olaparib results in increased expression of CDKN1A protein
INCB054329 promotes the reaction [olaparib results in increased expression of CDKN1A protein]; olaparib promotes the reaction [INCB054329 results in increased expression of CDKN1A protein]
CTD PMID:29567272 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Chek1 checkpoint kinase 1 increases phosphorylation ISO olaparib results in increased phosphorylation of CHEK1 protein CTD PMID:25531448 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA] CTD PMID:27984176 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Ctcf CCCTC-binding factor decreases binding ISO olaparib decreases binding of CTCF to Cp promoter region in human lymphoblastoid cell lines RGD PMID:29976663 RGD:151356754 NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of CXCL2 mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CXCL2 mRNA] CTD PMID:27984176 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO olaparib inhibits the reaction [Methylmercury Compounds results in increased expression of CYCS protein] CTD PMID:35396826 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein]
olaparib results in increased expression of DDIT3 protein
CTD PMID:25531448 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of FASN mRNA CTD PMID:27984176 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fh fumarate hydratase increases response to substance ISO FH mutant form results in increased susceptibility to olaparib CTD PMID:30013182 NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of GPT protein; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein] CTD PMID:27984176 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression
increases phosphorylation
ISO (+)-JQ1 compound promotes the reaction [olaparib results in increased expression of H2AX protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the expression of H2AX protein; [Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]; INCB054329 promotes the reaction [olaparib results in increased expression of H2AX protein]; olaparib promotes the reaction [(+)-JQ1 compound results in increased expression of H2AX protein]; olaparib promotes the reaction [INCB054329 results in increased expression of H2AX protein]; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of H2AX protein
CTD PMID:25531448 PMID:26544897 PMID:29567272 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions EXP olaparib inhibits the reaction [Ethanol results in increased expression of HMGB1 protein] CTD PMID:29339456 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of ICAM1 mRNA CTD PMID:27984176 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of IL1B mRNA CTD PMID:27984176 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions ISO olaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein] CTD PMID:29317476 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO
EXP
Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]
bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]
CTD PMID:34826546 PMID:36639873 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions
ISO olaparib results in decreased expression of MKI67 protein
INCB054329 promotes the reaction [olaparib results in decreased expression of MKI67 protein]; olaparib promotes the reaction [INCB054329 results in decreased expression of MKI67 protein]
CTD PMID:29567272 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Mlh1 mutL homolog 1 multiple interactions ISO olaparib inhibits the reaction [MLH1 protein results in decreased susceptibility to Floxuridine] CTD PMID:22194930 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of MPO protein CTD PMID:27984176 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Msh2 mutS homolog 2 multiple interactions ISO olaparib inhibits the reaction [MSH2 protein results in decreased susceptibility to Floxuridine] CTD PMID:22194930 NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
JBrowse link
G Msh3 mutS homolog 3 decreases response to substance ISO MSH3 protein results in decreased susceptibility to olaparib CTD PMID:21285347 NCBI chr 2:23,444,326...23,585,777 JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
decreases binding
decreases activity
ISO olaparib inhibits the reaction [Hydrogen Peroxide results in increased activity of PARP1 protein]
olaparib results in increased cleavage of PARP1 protein
(+)-JQ1 compound promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; [BRD4 protein affects the susceptibility to olaparib] which affects the cleavage of PARP1 protein; INCB054329 promotes the reaction [olaparib results in increased cleavage of PARP1 protein]; olaparib inhibits the reaction [Methylmercury Compounds results in increased cleavage of PARP1 protein]; olaparib promotes the reaction [INCB054329 results in increased cleavage of PARP1 protein]
olaparib decreases binding of PARP1 to Cp promoter region in human lymphoblastoid cell lines
olaparib results in decreased activity of PARP1 protein
CTD
RGD
PMID:24814482 PMID:28001384 PMID:29567272 PMID:35396826 PMID:29976663 RGD:151356754 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 multiple interactions ISO olaparib binds to and results in decreased activity of PARP2 protein CTD PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
decreases expression
ISO INCB054329 promotes the reaction [olaparib results in decreased expression of PCNA protein] CTD PMID:29567272 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pla2g2a phospholipase A2 group IIA multiple interactions EXP olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G2A protein] CTD PMID:29339456 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
JBrowse link
G Pla2g4a phospholipase A2 group 4A multiple interactions EXP olaparib inhibits the reaction [Ethanol results in increased expression of PLA2G4A protein] CTD PMID:29339456 NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of PPARA mRNA CTD PMID:27984176 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO [olaparib co-treated with INCB054329] results in decreased expression of RAD51 protein CTD PMID:29567272 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B increases response to substance ISO SDHB mutant form results in increased susceptibility to olaparib CTD PMID:30013182 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Sirt1 sirtuin 1 increases expression
multiple interactions
ISO olaparib results in increased expression of SIRT1 protein
olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of SIRT1 protein]
CTD PMID:34826546 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions EXP olaparib inhibits the reaction [Hydrogen Peroxide results in decreased expression of SQSTM1 protein] CTD PMID:36639873 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Dietary Fats co-treated with olaparib] results in decreased expression of SREBF1 mRNA CTD PMID:27984176 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA] CTD PMID:27984176 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [Ethanol co-treated with Dietary Fats co-treated with olaparib] results in decreased expression of TNF mRNA; olaparib inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; olaparib inhibits the reaction [Ethanol results in increased expression of TNF protein] CTD PMID:27984176 PMID:29317476 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions ISO [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein; CASP8 protein affects the reaction [[olaparib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [[TNFSF10 protein co-treated with olaparib] results in increased expression of TNFRSF10B protein] CTD PMID:25531448 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases phosphorylation
ISO [Fluorouracil co-treated with olaparib] results in increased expression of TP53 protein; TP53 gene mutant form affects the reaction [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Fluorouracil co-treated with olaparib] results in increased phosphorylation of H2AX protein]]
olaparib results in increased phosphorylation of TP53 protein
CTD PMID:25531448 PMID:26544897 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 multiple interactions ISO olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD] CTD PMID:35778544 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
JBrowse link
phenanthridone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO phenanthridone inhibits the reaction [Methylnitronitrosoguanidine results in increased localization of AIFM1 protein] CTD PMID:15589979 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP7 protein CTD PMID:29416738 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [eprenetapopt co-treated with phenanthridone] results in increased cleavage of CASP9 protein CTD PMID:29416738 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CCL3 protein] CTD PMID:12006805 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Cd83 CD83 molecule decreases expression ISO phenanthridone results in decreased expression of CD83 mRNA; phenanthridone results in decreased expression of CD83 protein CTD PMID:17579050 NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
JBrowse link
G Cd86 CD86 molecule decreases expression ISO phenanthridone results in decreased expression of CD86 mRNA; phenanthridone results in decreased expression of CD86 protein CTD PMID:17579050 NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein] CTD PMID:12006805 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions
ISO phenanthridone results in increased expression of H2AX protein modified form
Acetylcysteine inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]; TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]
CTD PMID:29416738 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Ifng interferon gamma multiple interactions
decreases expression
EXP phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA]
phenanthridone results in decreased expression of IFNG mRNA
CTD PMID:12411406 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 multiple interactions ISO phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] CTD PMID:17579050 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il12b interleukin 12B multiple interactions ISO phenanthridone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] CTD PMID:17579050 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il1b interleukin 1 beta decreases expression EXP phenanthridone results in decreased expression of IL1B mRNA CTD PMID:12411406 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 decreases expression
multiple interactions
EXP phenanthridone results in decreased expression of IL2 mRNA
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA]
CTD PMID:12411406 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Kif18a kinesin family member 18A increases metabolic processing ISO phenanthridone results in increased metabolism of KIF18A protein CTD PMID:28209915 NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
JBrowse link
G Kifc1 kinesin family member C1 increases metabolic processing ISO phenanthridone results in increased metabolism of KIFC1 protein CTD PMID:28209915 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
JBrowse link
G Nos2 nitric oxide synthase 2 decreases expression EXP phenanthridone results in decreased expression of NOS2 mRNA CTD PMID:12411406 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 decreases activity
multiple interactions
EXP
ISO
phenanthridone results in decreased activity of PARP1 protein
[eprenetapopt co-treated with phenanthridone] results in increased cleavage of PARP1 protein
CTD PMID:12411406 PMID:29416738 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression EXP phenanthridone results in decreased expression of PTGS2 mRNA CTD PMID:12411406 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
EXP
ISO
phenanthridone inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF mRNA]
phenanthridone analog inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]
phenanthridone results in decreased expression of TNF mRNA
CTD PMID:12006805 PMID:12411406 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
decreases expression
ISO TXNRD1 protein inhibits the reaction [phenanthridone results in increased expression of H2AX protein modified form]
phenanthridone results in decreased expression of TXNRD1 mRNA; phenanthridone results in decreased expression of TXNRD1 protein
CTD PMID:29416738 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
PJ34 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Itgam integrin subunit alpha M decreases expression EXP PJ34 decreases expression of Itgam mRNA and protein in ischemic brain RGD PMID:23151666 RGD:329902065 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
JBrowse link
rucaparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2l1 Bcl2-like 1 affects response to substance ISO BCL2L1 protein affects the susceptibility to rucaparib CTD PMID:32927276 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Brca1 BRCA1, DNA repair associated affects response to substance ISO BRCA1 protein affects the susceptibility to rucaparib CTD PMID:32927276 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brd4 bromodomain containing 4 affects response to substance ISO BRD4 protein affects the susceptibility to rucaparib CTD PMID:32927276 NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539
JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
ISO rucaparib results in increased expression of CASP3 protein
[Irinotecan co-treated with rucaparib] results in increased expression of CASP3 protein
CTD PMID:30612311 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO rucaparib inhibits the reaction [Ethanol results in increased expression of CCL2 protein] CTD PMID:29317476 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [rucaparib co-treated with Dasatinib] results in decreased expression of CCND1 protein CTD PMID:32927276 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cdk9 cyclin-dependent kinase 9 affects response to substance ISO CDK9 protein affects the susceptibility to rucaparib CTD PMID:32927276 NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
JBrowse link
G H2ax H2A.X variant histone multiple interactions
affects expression
ISO [Irinotecan co-treated with rucaparib] results in increased expression of H2AX protein; [rucaparib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased expression of H2AX protein; [rucaparib co-treated with Dasatinib] results in increased expression of H2AX protein
rucaparib affects the expression of H2AX protein
CTD PMID:30612311 PMID:32927276 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Il6 interleukin 6 multiple interactions ISO rucaparib inhibits the reaction [Ethanol results in increased expression of IL6 protein] CTD PMID:29317476 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Irinotecan co-treated with rucaparib] results in decreased expression of MKI67 protein CTD PMID:30612311 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases expression
ISO [rucaparib co-treated with Dasatinib co-treated with CPI-0610] results in increased cleavage of PARP1 protein; rucaparib binds to and results in decreased activity of PARP1 protein; rucaparib inhibits the reaction [Irinotecan results in increased expression of PARP1 protein]; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein]
rucaparib results in decreased expression of PARP1 protein
CTD PMID:28001384 PMID:30612311 PMID:32927276 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 decreases activity ISO rucaparib results in decreased activity of PARP2 protein CTD PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Irinotecan co-treated with rucaparib] results in decreased expression of RPS6KB1 protein CTD PMID:30612311 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase affects response to substance
multiple interactions
increases phosphorylation
ISO SRC protein affects the susceptibility to rucaparib
[rucaparib co-treated with Dasatinib] results in decreased phosphorylation of SRC protein
rucaparib results in increased phosphorylation of SRC protein
CTD PMID:32927276 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO rucaparib inhibits the reaction [Ethanol results in increased expression of TNF protein] CTD PMID:29317476 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnks2 tankyrase 2 affects binding ISO rucaparib binds to TNKS2 protein CTD PMID:28001384 NCBI chr 1:234,567,888...234,621,079
Ensembl chr 1:234,567,858...234,621,079
JBrowse link
veliparib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A increases transport ISO ABCB1 protein results in increased transport of veliparib CTD PMID:21436403 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] CTD PMID:30296409 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases activity
ISO veliparib results in increased phosphorylation of and results in increased activity of ATM protein
veliparib results in increased activity of ATM protein
CTD PMID:21917757 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] CTD PMID:18376143 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] CTD PMID:18376143 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib] CTD PMID:18376143 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Brca1 BRCA1, DNA repair associated affects response to substance
decreases response to substance
ISO BRCA1 affects the susceptibility to veliparib
BRCA1 protein results in decreased susceptibility to veliparib
CTD PMID:21633166 PMID:21707865 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brca2 BRCA2, DNA repair associated affects response to substance ISO BRCA2 affects the susceptibility to veliparib CTD PMID:21633166 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Cdk12 cyclin-dependent kinase 12 affects response to substance ISO CDK12 protein affects the susceptibility to veliparib CTD PMID:27880910 NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888
Ensembl chr10:83,201,211...83,280,888
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases metabolic processing ISO CYP1A2 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 increases metabolic processing ISO CYP2C19 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing ISO CYP2D6 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing ISO CYP3A4 protein results in increased metabolism of veliparib CTD PMID:21436403 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
affects localization
ISO EGFR protein results in decreased susceptibility to veliparib
veliparib affects the localization of EGFR protein
CTD PMID:21719137 PMID:21912620 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions ISO ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] CTD PMID:21227924 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit multiple interactions ISO ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] CTD PMID:21227924 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate] CTD PMID:25136123 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression
ISO [veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form
CTD PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA] CTD PMID:27444121 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Mpg N-methylpurine-DNA glycosylase multiple interactions ISO MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide] CTD PMID:21377995 NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
JBrowse link
G Mre11 MRE11 homolog, double strand break repair nuclease decreases response to substance ISO MRE11 protein results in decreased susceptibility to veliparib CTD PMID:21300766 NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] CTD PMID:27444121 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
decreases activity
increases expression
ISO PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]
veliparib results in decreased activity of PARP1 protein
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form
[veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin
CTD PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 affects binding ISO veliparib binds to PARP10 protein CTD PMID:28001384 NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304
JBrowse link
G Parp2 poly (ADP-ribose) polymerase 2 affects binding
multiple interactions
decreases activity
ISO PARP2 protein binds to veliparib
veliparib binds to and results in decreased activity of PARP2 protein
veliparib results in decreased activity of PARP2 protein
CTD PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384 NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
JBrowse link
G Pten phosphatase and tensin homolog decreases response to substance ISO PTEN protein results in decreased susceptibility to veliparib CTD PMID:20530668 NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
JBrowse link
G Rpa2 replication protein A2 multiple interactions ISO veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] CTD PMID:27694308 NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
JBrowse link
G S100b S100 calcium binding protein B multiple interactions ISO veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] CTD PMID:27444121 NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
JBrowse link
G Tdp1 tyrosyl-DNA phosphodiesterase 1 multiple interactions ISO TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] CTD PMID:21227924 NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 multiple interactions ISO veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD] CTD PMID:35778544 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19915
    role 19885
      biological role 19883
        biochemical role 19566
          enzyme inhibitor 18777
            EC 2.* (transferase) inhibitor 14970
              EC 2.4.* (glycosyltransferase) inhibitor 526
                EC 2.4.2.* (pentosyltransferase) inhibitor 263
                  EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor 257
                    2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide + 3
                    2-\{4-[(3R)-piperidin-3-yl]phenyl\}-2H-indazole-7-carboxamide 0
                    3-aminobenzamide 45
                    NU 1025 1
                    PJ34 1
                    PJ34 hydrochloride 0
                    isoquinoline-1,5-diol 7
                    mefuparib 0
                    mefuparib hydrochloride 0
                    nicotinamide + 167
                    niraparib 3
                    olaparib 58
                    phenanthridone 20
                    rucaparib 16
                    rucaparib camsylate 0
                    veliparib 30
paths to the root